ODI Pharma AB (publ) reported earnings results for the fourth quarter and full year ended June 30, 2022. For the fourth quarter, the company reported sales was SEK 0.014233 million. Revenue was SEK 0.050125 million compared to SEK 0.005308 million a year ago. Net loss was SEK 2.38 million compared to SEK 1.88 million a year ago. Basic loss per share from continuing operations was SEK 0.16 compared to SEK 0.12 a year ago.
For the full year, sales was SEK 0.544151 million. Revenue was SEK 0.632022 million compared to SEK 0.023667 million a year ago. Net loss was SEK 7.3 million compared to SEK 3.98 million a year ago. Basic loss per share from continuing operations was SEK 0.48 compared to SEK 0.26 a year ago.